Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Overview of all originally disseminated tumor cell (DTC)-positive patients with detectable DTCs by double immunofluorescence technique and clinicopathological parameters

From: NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Patient identifier Study BMA time pointsa NR2F1/AE1AE3 DIF analysis Ki67/AE1AE3 DIF analysis HR HER2 T status N status Time (months) from BMA to systemic relapse or BC death Relapse status or BC death (if not recorded relapse) Time (months) from BMA to last observation if no relapse Comment
No. of DTCs % NR2F1high DTCs No. of DTCs % Ki67+ DTCs
20 N (BM1)-BM3 35 0 7 28.6 pos nd 3 2 0.30 Bone and visceral   
74 S (BM1-BM3)-BM4 3 0 nd nd pos neg 1 1 1.09 Bone   
5 O (BM1)/BM2 1000 0 1000 15.0 pos pos 1 1 1.15 Bone   
60 S (BM2)-BM3 1000 0b 84 26,2 pos neg 2 1 1.84 Bone   
27 N (BM1)-BM2 5 0c nd nd neg nd 3 0 5.69 Visceral   
62 S BM2 40,000 0 nd nd pos neg 2 0 5.79 Bone and visceral   Chemo after BMA
4 O (BM1)-BM2 9 0 23 21.7 pos neg 3 1 7.50 Bone and visceral   
3 O BM1 11 0 nd nd pos neg 2 1 11.22 Visceral   
78 S (BM1)-BM2-(BM3) 26 0 29 13.8 pos neg 2 3 13.19 Bone and visceral   Chemo after BMA
13 O BM1 79 0 nd Nd neg pos 1 1 13.22 Bone   Chemo after BMA
17 N BM3 5 0 4 25.0 pos nd 3 1 17.57 Bone and visceral   
34 N BM1-(BM2) 2 0 nd nd pos neg 3 1 47.43 Visceral   Chemo after BMA
12 O BM2 16 0 nd nd pos neg 2 1   No relapse 57.73  
66 S BM1-(BM4) 3 0 nd nd pos neg 1 2   No relapse 87.50 Chemo after BMA
11 O (BM1)-BM2 500 1.0 87 66.7 neg pos 3 1 3.72 BC death   
23 N BM3 50 10.0 16 12.5 pos pos 3 0 13.55 BC death   
35 N (BM1)-BM3 7 14.3 12 25.0 pos nd 3 2 N/A d   Met. before BMA
48   (BM1)-BM3 17 25.5 10 20.0 pos nd 3 0 12.24 Bone   
41 N BM3 111 30.6 82 17.1 pos nd 4 1 N/A d   Met. before BMA
36 N (BM1)-BM3 6 50,0 4 50.0 pos nd 3 1 25.33 Bone   
84 S (BM1)-BM2 2 50.0 nd nd pos neg 2 2   No relapse 55.53 Chemo after BMA
9 O BM1 48 56.3 nd Nd neg neg 2 1 N/A Boned   Met. at BMA
85 S (BM1)-BM2 106 56.6 70 10.0 pos neg 2 2   No relapse 56.02 Chemo after BMA
69 S (BM1)-BM2-(BM3) 52 65.4 35 0 pos neg 2 2 15.10 Visceral   Chemo after BMA
6 O (BM1)-BM2 233 94.9 400 1.0 neg pos 1 1 N/A Visceral   Met. before BMA
57 S (BM3)-BM4 6 100 nd nd neg nd 2 0   No relapse 59.93  
  1. BC breast cancer, Chemo chemotherapy, DIF double immunofluorescence, HR hormone receptor, Met. metastasis, N Neotax, N/A not applicable, nd not determined, neg negative, O Oslo1, pos positive, S SATT
  2. aThe bone marrow aspiration (BMA) time points for each patient are noted. In this table, the DTC results are only presented for the BMAs highlighted in bold (last positive sample); results from the other BMA time points are available in Additional file 1 (Table S1) and partly in Fig 3
  3. bIn the first bone marrow (BM) sample, 46.3% of the DTCs were NR2F1high
  4. cIn the first BM sample, 33.3% of the DTCs were NR2F1high
  5. dMetastasis before BMA